MetaCap

Werewolf Therapeutics (HOWL) vs Tonix Pharmaceuticals (TNXP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Werewolf Therapeutics (HOWL) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, gaining 8.4% versus a loss of 85.2%. Over five years, HOWL leads with a -93.7% price change compared with -100.0% for TNXP. Tonix Pharmaceuticals is the larger company by market cap ($46.2 million vs $46.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HOWL+8.43%TNXP-85.22%
+32%-30%-91%
Nov 21, 20251 yearNov 20, 2026
HOWL-94.08%TNXP-100.00%
+12%-47%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HOWL versus TNXP key metrics
MetricHOWLTNXP
Share price$0.9466$2.38
Market cap$46.00M$46.25M
1-day change-3.97%-6.67%
YTD return+49.31%-84.76%
1-year return+8.43%-85.22%
5-year return-93.68%-100.00%
EPS (TTM)$-0.58$-12.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$13.11M
Revenue growth (YoY)—+29.85%
Net income (latest FY)$-60.82M$-124.02M
Gross margin—49.34%
Operating margin—-959.05%
Net margin—-946.22%
52-week high$1.20$20.56
52-week low$0.27$2.30
Distance from 52-week high-21.12%-88.42%
Analyst consensusnonestrong_buy
Avg. price target upside+639.49%+1769.75%
Average volume1.08M838.83K
Shares outstanding48.60M19.43M
Employees39142
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HOWL has outperformed TNXP by 93.6 percentage points over the past year.

About Werewolf Therapeutics

HOWL stock →

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees

About Tonix Pharmaceuticals

TNXP stock →

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.

Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees

HOWL vs TNXP FAQ

Which is bigger, Werewolf Therapeutics or Tonix Pharmaceuticals?

Tonix Pharmaceuticals (TNXP) is larger, with a market capitalization of $46.25M compared with $46.00M for Werewolf Therapeutics (HOWL).

Which stock has performed better over the past year, HOWL or TNXP?

HOWL returned +8.43% over the past 12 months, compared with -85.22% for TNXP (price return, excluding dividends). Past performance does not predict future results.

Are Werewolf Therapeutics and Tonix Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons